Liver Cancer | Tumor

CURE’s liver cancer page features the latest cancer news and updates on liver cancer Through articles, videos, podcasts, and more, CURE brings readers the insights of experts, cancer survivors, patients, and advocates to ensure everyone is up to date in liver cancer.

Immunotherapy Use Increased in Patients Ineligible for Cancer Trials, Highlighting the Need for More Research in Vulnerable Populations

December 28th 2021

The use of immunotherapy in patients with advanced cancers and decreased fitness levels or organ function increased from 2014 to 2019, although trials for this treatment typically exclude this population.

Top 5 Liver Cancer-Related Stories in 2021

December 22nd 2021

CURE® took a look back at our most-read liver cancer stories from this year.

Noninvasive Bridging Therapy Underutilized Versus More Invasive Options in Transplant-Eligible Hepatocellular Carcinoma

November 8th 2021

External-beam radiation, a noninvasive option for bridging therapy, may be underused compared with other liver-directed therapies and may highlight a treatment gap in this area.

Vietnam Veterans With Cholangiocarcinoma Get Help to Navigate Filing Claims With the VA in Commemoration of Veterans Day

November 5th 2021

Cholangiocarcinoma Foundation volunteer Lourdes Rocha leads the Veterans Program and shares her experience filing claims with the VA in a recorded webinar.

Side Effects From Immune Checkpoint Inhibitors May Increase Hospitalizations, Cost for Patients With Bladder, Liver, Lung or Skin Cancer

November 4th 2021

Patients who experience side effects due to immune checkpoint inhibitors are 80% more likely to go to the emergency room and have 30% higher monthly medical costs, compared to patients who did not have side effects.

Tremelimumab Plus Imfinzi Regimen Boosts Liver Cancer Survival

October 15th 2021

Data from a phase 3 trial show that frontline tremelimumab plus Imfinzi improved overall survival in patients with liver cancer.

Liver Cancer Increasing in Rural Areas of the United States

October 15th 2021

The results, according to one of the study’s authors, indicate that liver cancer is an underrecognized and deadly cancer that is increasingly affecting people living in rural areas of the United States.

Chemo/Immunotherapy Approach Is Promising in Intermediate-Stage Liver Cancer

September 29th 2021

The new approach of chemotherapy plus Opdivo offers “the best of both treatment approaches,” says one expert.

Patients with Liver Cancer and Hepatitis or HIV May Face Higher Mortality Rates

September 24th 2021

Results from the study highlight the need to organize better screening and treatment plans for patients with liver cancer coinfected with hepatitis B, hepatitis C or HIV.

‘Landmark’ FDA Approval of Tibsovo May Improve Outcomes for Liver Cancer Subtype

September 3rd 2021

The FDA approval of Tibsovo marks the first targeted therapy for patients with this liver cancer subtype.

Tibsovo For The Treatment of Liver Cancer Subtype Receives FDA Approval

August 25th 2021

Tibsovo — which is the first targeted therapy approved for this patient population — improved survival in patients with a subtype of liver cancer.

Older Liver Cancer Survivors Are Less Informed About Life After Cancer

August 5th 2021

The results, according to the study authors, demonstrate a need to better inform older patients during treatment about survivorship after liver cancer.

Opdivo Regimen Pulled for Liver Cancer Treatment

July 28th 2021

Opdivo was granted an accelerated approval for patients with hepatocellular carcinoma, but the indication was pulled after follow-up data failed to show that the agent improved survival over another drug.

Researchers Discover a Culprit Behind Aggressive Liver Cancer

July 12th 2021

Patients whose disease contained the osteopontin protein tended to have more aggressive liver cancer that did not respond to treatment.

COVID-19 Pandemic Had Significant Impact on Liver Cancer Screenings and Care

July 9th 2021

Screening and diagnostic procedures for liver cancer as well as transplant programs and curative/palliative treatments were modified or delayed due to the COVID-19 pandemic, a new survey says.

Alcohol-Cancer Link Needs More Recognition

July 8th 2021

Most people surveyed knew about the link between alcohol and liver cancer, but far fewer knew that drinking could increase breast cancer risk, too.

Two-Drug Combo Shows Modest Benefit in Biliary Tract Cancer

June 15th 2021

Treatment with the combination of Stivarga and Bavencio was associated with minor anti-tumor activity in patients with advanced, heavily pretreated biliary tract solid tumors.

Onivyde Combo Improves Outcomes for Patients with Metastatic Liver Cancer

June 8th 2021

Onivyde combined with a chemotherapy agent and a chemotherapy-protective drug should be used as a second-line treatment option in patients with metastatic liver cancer, according to an expert.

5 Recent Cancer Drug Approvals That Patients May Have Missed

June 3rd 2021

The Food and Drug Administration has had a busy couple of weeks, approving several agents to treat a variety of cancers. Here are five recent approvals that patients with cancer may have missed.

FDA Grants Approval for Truseltiq for Metastatic Cholangiocarcinoma Treatment

May 29th 2021

The FDA approved a kinase inhibitor for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with FGFR2 fusion or other arrangement.

Second-Line Chemotherapy Combo Shows Survival Benefit in Patients With Advanced Liver Cancer

May 26th 2021

The study results, according to the authors, suggest that the combination of folinic acid plus the chemotherapies fluorouracil and oxaliplatin should become the standard-of-care therapy in patients with advanced biliary tract cancer whose disease progressed with cisplatin and gemcitabine.

Neoadjuvant Libtayo Shows Promise for Patients With Hepatocellular Carcinoma

May 10th 2021

Twenty percent of patients with resectable hepatocellular carcinoma had a significant amount of cell death when receiving Libtayo before surgical intervention.

Derazantinib May Demonstrate Promising Disease Control in Some Patients With Cholangiocarcinoma

May 7th 2021

Interim results from a phase 2 study demonstrated that patients inoperable or advanced intrahepatic cholangiocarcoma and a FGFR2 gene mutation had a disease control rate of 79% when treated with derazantinib.

FDA Panel Votes to Uphold One Accelerated Drug Approval, and Overturn Another in Treatment of Advanced Liver Cancer

May 4th 2021

Members of an FDA committee recently voted in favor of upholding Keytruda’s accelerated approval indication for the treatment of patients with advanced hepatocellular carcinoma who had previously received treatment with Nexavar. However, the committee narrowly voted against maintaining Opdivo’s accelerated approval in the same patient population.

Tag Teaming Liver Cancer Care

April 30th 2021

As part of the “Speaking Out” video series, CURE® spoke with Dr. Laura M. Kulik about the basics of liver cancer, highlighting the need for a multidisciplinary approach to care.

CURE’s Clinical Trial Corner: April 2021

April 29th 2021

Here is a list of some recent trials that launched within the cancer space in April.

MET Inhibitor May Be Effective in Treating Patients With Hepatocellular Carcinoma With MET Overexpression Who Were Not Successful With Nexavar

April 13th 2021

A 500 mg dose of Tepmetko, a MET inhibitor, in patients with hepatocellular carcinoma who were previously treated with Nexavar led to a 12-week progression-free survival rate of 63.3%.

Raising Awareness Around Liver Cancer and Disease

April 9th 2021

CURE spoke with Dr. Marty T. Sellers and Dr. Laura M. Kulik, on behalf of the Blue Faery, about liver cancer and disease – its treatments, causes and areas outside of therapy.

FDA Approves Radiation Therapy for Outpatient Setting in Liver Cancer Subtype

March 19th 2021

Patients with this liver cancer subtype do not need to be hospitalized to receive this treatment and, according to the agent’s manufacturer, Boston Scientific, can typically receive the therapy in approximately an hour during an outpatient procedure.

Genomic Testing Offers New Therapy Options for Hepatobiliary Cancers

March 17th 2021

Genomic testing has allowed patients to receive more specific drugs that target mutations in their tumors.

NEXT PAGE
PREVIOUS PAGE